AkesoFRA:4RY +6.67%54 Buyback Yield % is -3.75 as of Jul. 06, 2026. GuruFocus rates FRA:4RY with a GF Score™ of 54/100 and a GF Value™ of €15.94 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 741 Biotechnology companies, Akeso ranks better than 62.62% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Akeso's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:4RY vs VRTX, REGN, ALNY: Buyback Yield % Comparison
For the Biotechnology subindustry, Akeso's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Akeso Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Akeso's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Akeso's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Akeso (FRA:4RY) has a Buyback Yield % of -3.75 as of Jul. 06, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Akeso and its competitors. According to the industry distribution chart, Akeso ranks #277 out of 741 companies in the Biotechnology industry, placing it in the top 37.4%.
Is Akeso's Buyback Yield % too high?
Akeso's current Buyback Yield % is -3.75. Based on the distribution chart, Akeso ranks #277 out of 741 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Akeso has a GF Score™ of 54/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Akeso's Buyback Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Akeso ranks #277 out of 741 companies for Buyback Yield %. This puts Akeso in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Akeso and its competitors. Akeso's current Buyback Yield % is -3.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akeso stock overvalued right now?
Based on GuruFocus' analysis, Akeso (FRA:4RY) is currently considered Modestly Undervalued. The stock's GF Value™ is €15.94, compared to a current price of €11.28 — trading 29.2% below its estimated fair value. The current Buyback Yield % is -3.75. Akeso's overall GF Score™ is 54/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Akeso (FRA:4RY), the current Buyback Yield % is -3.75 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Akeso (FRA:4RY) Overvalued in 2026?
Based on GuruFocus' analysis, Akeso stock appears to be undervalued.
The current stock price of €11.28 is trading 29.2% below its estimated GF Value™ of €15.94.
GuruFocus considers Akeso to be Modestly Undervalued.
Key valuation signals for FRA:4RY:
Buyback Yield %: -3.75
GF Value™: €15.94 vs. price of €11.28 (29.2% below fair value)
No single metric tells the full story. See the FRA:4RY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Akeso Inc is an investment holding company. The Company's subsidiaries were involved in research and development, production, and commercialization of biopharmaceutical products. The company has developed more than 50 drug candidates, including 15 bispecific antibody/multispecific antibody/bispecific antibody ADC/ADC/TCE drugs, with 27 drugs in clinical development. The majority of the company's revenue is derived from Mainland China, and it also has its presence in the USA and Other regions.
54GF Score
Get the complete analysis for FRA:4RY
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4RY has been successfully added to your 
